Takeda Pharmaceutical Co Ltd (4502.T)
18 Apr 2014
|Market Cap (Mil.):||¥3,590,678.00|
|Shares Outstanding (Mil.):||789.68|
For the full text of this story please click the following link:
SAN FRANCISCO/TOKYO - Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by a jury in the United States in a case that accused Japan's largest drugmaker of concealing cancer risks associated with its Actos diabetes drug.
* Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly
SAN FRANCISCO/TOKYO - Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by a U.S. federal jury in a case alleging that Japan's largest drugmaker had concealed cancer risks associated with its Actos diabetes drug.
TOKYO, April 8 - Japanese shares fell 1.4 percent to a two-week low on Tuesday as Takeda Pharmaceutical Co tumbled after a U.S. jury ordered it to pay $6 billion over claims it concealed risks associated with its Actos diabetes drug. Gains in the yen also hurt sentiment, while tech stocks extended declines into a second day. During the session, the Bank of Japan stood pat on policy as expected after a two-day policy meeting. The Nikkei share average lost 201.97 points to
April 8 - A U.S. jury ordered Takeda Pharmaceutical Co Ltd to pay $6 billion in punitive damages and Eli Lilly and Co to pay $3 billion in a case claiming that cancer risks to the diabetes drug Actos were concealed, the plaintiffs' lawyer said.
TOKYO - Shares in Takeda Pharmaceutical Co Ltd were down nearly 6 percent on Tuesday morning after Bloomberg news reported that a U.S. jury ordered it to pay $6 billion in punitive damages in a case claiming it hid cancer risks of its Actos diabetes drug.
TOKYO, April 8 - Shares in Takeda Pharmaceutical Co Ltd were down nearly 6 percent on Tuesday morning after Bloomberg news reported that a U.S. jury ordered it to pay $6 billion in punitive damages in a case claiming it hid cancer risks of its Actos diabetes drug.
TOKYO, March 31 - Takeda Pharmaceutical Co Ltd and Dainippon Sumitomo Pharma Co Ltd said on Monday the European Commission had given them marketing authorisation for Latuda, a once-a-day oral treatment for schizophrenia in adults.
LONDON - European regulators have recommended approval of a new pill for hepatitis C from Johnson & Johnson, underscoring the rapid development of oral treatment options for the liver-destroying disease.
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Takeda Pharmaceutical Co Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: MarketLine (a Datamonitor Company)
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.